Zura Bio Grants 890,950 Stock Options to New CFO and Key Hires

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Very Positive)

Tags

07/17/2025 - 04:30 PM

HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (鈥淶ura Bio鈥� or the 鈥淐ompany鈥�), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported that on July 15, 2025, the Company granted inducement awards consisting of options to purchase up to 890,950 Class A Ordinary Shares (the 鈥淥ptions鈥�) to seven newly hired employees, which includes an award of 672,000 Options granted to Eric Hyllengren, the newly appointed Chief Financial Officer. These awards were approved by the Compensation Committee and the Board and granted outside the Company鈥檚 2023 Equity Incentive Plan (the 鈥淧lan鈥�), with a grant date of July 15, 2025, as inducements material to the new employees鈥� employments, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are subject to the terms and conditions and other provisions set forth in the Company鈥檚 Plan and the award agreements thereunder.

One fourth (1/4th) of the shares subject to each Option shall vest on the applicable vesting commencement date, and one twelfth (1/12th) of the remaining shares subject to each Option shall vest in equal quarterly installments thereafter, subject to the employee鈥檚 continuous service through such vesting date.

ABOUT ZURA BIO

Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases. The Company鈥檚 pipeline includes dual-pathway product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.

Zura Bio鈥檚 lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies in adults, including TibuSURE for systemic sclerosis and TibuSHIELD for hidradenitis suppurativa. Additional product candidates, crebankitug (ZB-168) and torudokimab (ZB-880), have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.

For more information, please visit .